AbbVie announces $380m investment in North Chicago API facilities

AbbVie has announced plans to put $380m to conception 2 caller progressive pharmaceutical constituent (API) manufacturing facilities astatine its existent North Chicago tract successful Illinois, US.

These facilities volition integrate precocious manufacturing technologies and AI for supporting accumulation of the company's obesity and next-generation neuroscience medications.

Construction is scheduled to commence successful outpouring 2026, with some facilities anticipated to beryllium afloat operational by 2029.

AbbVie intends to enlistee 300 employees successful North Chicago, including manufacturing operators, scientists, laboratory technicians, and engineers, to enactment the expanded operations.

Manufacturing APIs is simply a multi-step and intricate process that creates the components indispensable for a medication’s therapeutic effects.

Over the past six months, AbbVie has revealed plans to considerably summation its API manufacturing capableness successful the US.

In September 2025, the institution broke crushed connected the archetypal signifier of this investment, a chemic synthesis installation aimed astatine relocating API accumulation for definite neuroscience, immunology, and oncology products from Europe and Asia backmost to the US.

AbbVie employs astir 29,000 radical successful the US, including implicit 6,000 astatine its manufacturing sites successful the US.

In summation to the latest investment, recently, AbbVie revealed plans for a instrumentality manufacturing installation acquisition successful Arizona and to marque important investments astatine its tract successful Massachusetts. Further investments successful different US states are expected to beryllium announced successful 2026.

AbbVie president and CEO Robert Michael said: “This milestone demonstrates further advancement against our $100bn committedness to US R&D and superior investments implicit the adjacent decade.

“By strengthening our US manufacturing capabilities, we are well-positioned to enactment our concern successful innovation and heighten our quality to present next-generation medicines to patients.”

In August 2025, AbbVie signed a definitive statement to get Gilgamesh Pharmaceuticals’ pb investigational candidate, bretisilocin, for up to $1.2bn, including an upfront outgo and improvement milestones.

"AbbVie announces $380m concern successful North Chicago API facilities" was primitively created and published by Pharmaceutical Technology, a GlobalData owned brand.

The accusation connected this tract has been included successful bully religion for wide informational purposes only. It is not intended to magnitude to proposal connected which you should rely, and we springiness nary representation, warranty oregon guarantee, whether explicit oregon implied arsenic to its accuracy oregon completeness. You indispensable get nonrecreational oregon specializer proposal earlier taking, oregon refraining from, immoderate enactment connected the ground of the contented connected our site.